Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Matt Barasch
King PharmaceuticalsKGWEAK BUYAug 22, 2003
Generic drug makers have been on quite a role.A good group to have exposure to.This company has FCC and business model problems.Risky.
Matt BaraschUnknown
$13.97
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PAST TOP PICK
(A top pick Aug 12/03. Up 3%.) Still likes. An outstanding value for investors to focus on.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Has great value. US Healthcare looks very inexpensive.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Will be volatile. An OK company at a bargain price. Good risk/reward.
Peter Arender, CFAOwned
biotechnologypharmaceutical
TOP PICK
(Was a top pick on July 14, 2003.Up 15%.)Still likes.Good earnings. Came out with a relatively good performance report.Got hit by a sudden move of defense money moving into cyclical areas.Got too cheap.
Brian Acker, CAOwned
biotechnologypharmaceutical
